Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Berenberg Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK)

Tipranks - Tipranks - Sat Mar 28, 1:36AM CDT

In a report released yesterday, from Berenberg Bank maintained a Hold rating on GlaxoSmithKline, with a price target of $54.00. The company’s shares closed yesterday at $53.94.

Claim 30% Off TipRanks Premium

In addition to Berenberg Bank, GlaxoSmithKline also received a Hold from TipRanks – OpenAI’s OpenAI Drug Manufacturers – General in a report issued on March 25. However, on the same day, TipRanks – xAI reiterated a Buy rating on GlaxoSmithKline (NYSE: GSK).

See Insiders’ Hot Stocks on TipRanks >>

Based on GlaxoSmithKline’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $8.62 billion and a net profit of $636 million. In comparison, last year the company earned a revenue of $8.12 billion and had a net profit of $414 million

Read More on GSK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).